Consensus Assembly Biosciences, Inc.

Stocks

ASMB

US0453962070

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 28/10/2026 +03			5-day change	1st Jan Change
20.57 ^USD	+1.33%		+0.54%	-39.52%

10-05	Assembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver Meeting	CI
10-05	Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program	MT

Evolution of the Average Target: Assembly Biosciences, Inc.

Evolution of the Target Price: Assembly Biosciences, Inc.

Changes in Analyst Recommendations: Assembly Biosciences, Inc.

84fe1.ZOPhZyacD4Msc-O65GGkR1Csf8n9IlmRwWoxHUtQSKg.UdqjAWXGartlQpLRnT7mdGjlDoykGzvftSR1cAYeJ-4IttE_abF88n5Bqg~f7e36b0234e7dd59a74a52dde613614f

Analysts' recommendations: Assembly Biosciences, Inc.

09-01	UBS Initiates Assembly Biosciences at Buy With $52 Price Target	MT
06-15	Mizuho Raises Price Target on Assembly Biosciences to $45 From $40, Keeps Outperform Rating	MT
11-20	Mizuho Raises Price Target on Assembly Biosciences to $40 From $29, Keeps Outperform Rating	MT
10/10/25	Assembly Biosciences, Inc. Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections Europe	CI
06/08/25	Assembly Biosciences Q2 revenue rises from Gilead collaboration	RE
21/05/25	Mizuho Cuts Price Target on Assembly Biosciences to $29 From $36, Keeps Outperform Rating	MT
25/03/25	Guggenheim Initiates Assembly Biosciences at Buy With $31 Price Target	MT
20/09/24	Jefferies Upgrades Assembly Biosciences to Buy From Hold, Adjusts PT to $35 From $24	MT
24/03/23	HC Wainwright Adjusts Price Target on Assembly Biosciences to $1.50 From $2.50, Keeps Neutral Rating	MT
15/11/22	Mizuho Cuts Price Target on Assembly Biosciences to $3 From $14, Keeps Buy Rating	MT
24/10/22	Truist Securities Downgrades Assembly Biosciences to Hold From Buy, Adjusts Price Target to $2 From $11	MT
21/07/22	HC Wainwright Adjusts Assembly Biosciences Price Target to $2.50 From $3,50, Maintains Buy Rating	MT
01/04/22	Truist Securities Adjusts Assembly Biosciences Price Target to $12 From $15, Maintains Buy Rating	MT
13/09/21	Assembly Biosciences : HC Wainwright Starts Assembly Biosciences at Neutral with $3.50 Price Target	MT
02/09/21	Assembly Biosciences : William Blair Downgrades Assembly Biosciences to Market Perform From Outperform	MT
12/08/21	Assembly Biosciences : Mizuho Securities Adjusts Price Target on Assembly Biosciences to $14 From $13 on Lower Expenses, Reiterates Buy Rating	MT
10/05/21	Assembly Biosciences : SVB Leerink Adjusts Price Target for Assembly Biosciences to $7 From $8, Maintains Market Perform Rating	MT
23/03/21	Assembly Biosciences : SVB Leerink Downgrades Assembly Biosciences to Market Perform From Outperform, Adjusts PT to $8 From $9	MT
21/12/20	Assembly Biosciences : Jefferies Adjusts Price Target for Assembly Biosciences to $7 From $10, Maintains Hold Rating	MT
04/12/20	Assembly Biosciences : Mizuho Adjusts Assembly Biosciences' PT to $13 From $30 After H0731 'Failure in Finite Therapy;' Buy Rating Kept on Undervalued Chronic Suppressive Therapy	MT
06/11/20	Assembly Biosciences : Jefferies Downgrades Assembly Biosciences to Hold From Buy; Price Target is $10	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ASSEMBLY BIOSCIENCES, INC.					+156.16%
	WUXI APPTEC CO., LTD.					+41.32%
	ARGENX SE					+28.63%
	LONZA GROUP AG					+9.56%
	IQVIA HOLDINGS INC.					+12.15%
	BEONE MEDICINES AG					+19.23%
	REVOLUTION MEDICINES, INC.					+39%
	CELLTRION, INC.					+42.31%
	GENMAB A/S					+6.5%
	WUXI BIOLOGICS (CAYMAN) INC.					+35.02%
	Average					+38.99%
	Weighted average by Cap.					+25.96%